ANI Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Unaudited consolidated results; comparisons are with the three months ended March 31, 2022. Amounts are in U.S. dollars.
Business context
ANI develops, manufactures, and markets generic, established-brand, and rare-disease prescription pharmaceuticals. Its rare-disease segment consists of Cortrophin Gel. The company’s strategy emphasizes growing that franchise, expanding generic development, and strengthening established brands. ANI completed the transfer of products from its Oakville, Ontario facility to U.S. sites and is seeking a buyer for the Oakville property.
Financial performance and liquidity
- Revenue: $106.8 million, up 65.6% from $64.5 million. Generics, established brands, and other revenue was $90.5 million, up 43.2%; rare-disease revenue, entirely Cortrophin Gel, was $16.3 million versus $1.3 million.
- Profitability: Operating income was $9.9 million, compared with an operating loss of $19.2 million. Net income was $1.4 million versus a net loss of $20.1 million. Net income available to common shareholders was $1.0 million; diluted EPS was $0.06 versus a loss of $1.27 per share.
- Margins: Cost of sales, excluding depreciation and amortization, was 35.3% of revenue versus 53.2%. Operating margin was 9.2% versus negative 29.8%. The filing attributes the lower cost-of-sales ratio partly to the nonrecurrence of $3.8 million of acquired-inventory expense recognized in Q1 2022 and to higher Cortrophin Gel sales.
- Cash flow: Operating activities generated $21.4 million, compared with $18.9 million used in Q1 2022. Investing activities used $2.4 million, primarily for capital expenditures; financing activities used $4.5 million, including debt payments, preferred dividends, and treasury shares withheld for restricted-stock taxes. Cash and cash equivalents were $67.8 million at quarter-end, up from $48.2 million at December 31, 2022.
- Debt and liquidity: Term Facility principal was $296.3 million, with a 9.14% interest rate at quarter-end; its maturity is November 2027. The $40.0 million revolving facility was undrawn and available subject to conditions. Current assets were $364.8 million and current liabilities $125.8 million. The company stated it expects available resources to cover working-capital needs and debt obligations for at least 12 months.
- Other metrics: Segment EBITDA was $38.8 million for Generics, Established Brands, and Other, and negative $1.3 million for Rare Disease. Interest expense, net, rose to $7.7 million from $6.6 million.
Material changes versus Q1 2022
- Revenue increased by $42.3 million, reflecting higher generic sales, growth in established brands and related services, and the continued Cortrophin Gel launch ramp.
- SG&A increased 26.6% to $36.5 million, primarily from higher Cortrophin Gel sales and marketing costs and headcount-related expenses. R&D rose 12.3% to $5.9 million.
- ANI moved from a substantial operating and net loss to positive operating and net income. The comparison also reflects a $5.8 million tax benefit in Q1 2022 versus a $0.7 million tax provision in Q1 2023.
- Oakville-related restructuring expense was $1.1 million in Q1 2023; no comparable expense was recorded in Q1 2022.
Outlook, risks, contingencies, and unusual items
- Management plans to continue investing in Cortrophin Gel and its rare-disease platform in 2023 and beyond. The filing provides no specific financial guidance or quantified forecast.
- Key risks include generic competition and price erosion, dependence on single-source API suppliers, supply-chain and manufacturing disruptions, regulatory approvals, product acceptance, and interest-rate exposure. A 1 percentage-point rate movement was estimated to change annualized interest expense by approximately $1.4 million on unhedged term debt.
- Three customers each accounted for at least 10% of revenue; together they represented 62% of Q1 2023 revenue and 83% of quarter-end accounts receivable.
- Two products marketed without approved NDAs or ANDAs generated $3.7 million of Q1 2023 revenue. Contract manufacturing for another group of unapproved products generated $0.6 million.
- ANI reported ongoing litigation and regulatory matters, including ranitidine-related claims involving Novitium and an appeal in the Bystolic antitrust litigation, which was dismissed with prejudice at the district court. The company says outcomes are uncertain and does not provide a clear estimate of reasonably possible material losses for the described matters.
- Controls: Management concluded disclosure controls and procedures were ineffective as of March 31, 2023 because remediation of previously identified material weaknesses in internal control over financial reporting was ongoing. Remediation included hiring a corporate controller, adding accounting resources, and progressing ERP and procure-to-pay controls.
- Other notable items include a $36.0 million contingent-consideration liability related to the Novitium acquisition and $8.0 million of Oakville land and building classified as held for sale.
Important facts for investors to verify
- Whether Cortrophin Gel’s sales growth and segment economics continue to improve, and how commercialization spending affects profitability.
- Customer concentration, collections, and the estimates underlying chargebacks, rebates, returns, and other revenue allowances.
- Debt covenant compliance, interest-rate exposure, and the company’s stated liquidity outlook.
- Progress on internal-control remediation and whether disclosure controls are subsequently assessed as effective.
- Developments in material litigation and regulatory matters, including potential financial exposure and insurance coverage.
- Whether the Oakville property is sold, on what terms, and whether additional closure costs or proceeds arise.